Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP - Get Free Report) shares were down 3.7% on Thursday . The company traded as low as $0.32 and last traded at $0.35. Approximately 51,497,243 shares changed hands during mid-day trading, an increase of 103% from the average daily volume of 25,332,580 shares. The stock had previously closed at $0.36.
Analyst Ratings Changes
Separately, StockNews.com initiated coverage on shares of Tonix Pharmaceuticals in a research report on Sunday. They set a "sell" rating for the company.
Check Out Our Latest Analysis on Tonix Pharmaceuticals
Tonix Pharmaceuticals Stock Up 56.3 %
The stock has a market capitalization of $106.53 million, a P/E ratio of -0.01 and a beta of 2.23. The company has a debt-to-equity ratio of 0.07, a current ratio of 3.33 and a quick ratio of 2.81. The firm has a 50-day simple moving average of $0.19 and a 200 day simple moving average of $0.52.
Tonix Pharmaceuticals (NASDAQ:TNXP - Get Free Report) last posted its earnings results on Tuesday, November 12th. The company reported ($0.23) earnings per share for the quarter, topping analysts' consensus estimates of ($2.03) by $1.80. The firm had revenue of $2.82 million for the quarter, compared to analyst estimates of $2.63 million. Tonix Pharmaceuticals had a negative net margin of 1,197.86% and a negative return on equity of 163.95%. On average, equities research analysts forecast that Tonix Pharmaceuticals Holding Corp. will post -17.63 EPS for the current year.
Tonix Pharmaceuticals Company Profile
(
Get Free Report)
Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.
Read More
Before you consider Tonix Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tonix Pharmaceuticals wasn't on the list.
While Tonix Pharmaceuticals currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Keep reading to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
